These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 8617977

  • 1. Lack of IL-2 cytokine expression despite Il-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers.
    Coventry BJ, Weeks SC, Heckford SE, Sykes PJ, Bradley J, Skinner JM.
    J Immunol; 1996 May 01; 156(9):3486-92. PubMed ID: 8617977
    [Abstract] [Full Text] [Related]

  • 2. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes.
    Lopez CB, Rao TD, Feiner H, Shapiro R, Marks JR, Frey AB.
    Cell Immunol; 1998 Dec 15; 190(2):141-55. PubMed ID: 9878115
    [Abstract] [Full Text] [Related]

  • 3. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
    Evans R, Kamdar SJ, Duffy T, Edison L.
    J Immunol; 1993 Jan 01; 150(1):177-84. PubMed ID: 8417123
    [Abstract] [Full Text] [Related]

  • 4. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
    Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM.
    Cancer Res; 1993 Mar 15; 53(6):1380-7. PubMed ID: 8443817
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-2 activated microglia engulf tumor infiltrating T cells in the central nervous system.
    Tamakawa N, Saio M, Suwa T, Ohe N, Yoshimura S, Iwama T, Shinoda J, Sakai N, Takami T.
    Int J Mol Med; 2004 Apr 15; 13(4):497-503. PubMed ID: 15010848
    [Abstract] [Full Text] [Related]

  • 6. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP, Hermonat PL.
    Gynecol Oncol; 2001 Jun 15; 81(3):424-32. PubMed ID: 11371133
    [Abstract] [Full Text] [Related]

  • 7. The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival.
    Barth RJ, Camp BJ, Martuscello TA, Dain BJ, Memoli VA.
    Cancer; 1996 Sep 15; 78(6):1168-78. PubMed ID: 8826937
    [Abstract] [Full Text] [Related]

  • 8. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
    Tian JQ, Wang ZP, Rodriguez R, Fu JS, Lu JZ, Ma BL.
    Urology; 2006 May 15; 67(5):1093-8. PubMed ID: 16635513
    [Abstract] [Full Text] [Related]

  • 9. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
    Kooi S, Zhang HZ, Patenia R, Edwards CL, Platsoucas CD, Freedman RS.
    Cell Immunol; 1996 Dec 15; 174(2):116-28. PubMed ID: 8954611
    [Abstract] [Full Text] [Related]

  • 10. A novel role of metalloproteinase in cancer-mediated immunosuppression.
    Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH.
    Cancer Res; 2001 Jan 01; 61(1):237-42. PubMed ID: 11196168
    [Abstract] [Full Text] [Related]

  • 11. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 01; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Levêque J, Guillé F, Patard JJ, Lesimple T, Catros-Quemener V.
    Eur Cytokine Netw; 2000 Jun 01; 11(2):217-24. PubMed ID: 10903800
    [Abstract] [Full Text] [Related]

  • 13. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes.
    Miescher S, Whiteside TL, Carrel S, von Fliedner V.
    J Immunol; 1986 Mar 01; 136(5):1899-907. PubMed ID: 2936812
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
    Koyama S, Koike N, Adachi S.
    J Cancer Res Clin Oncol; 2002 Feb 01; 128(2):73-9. PubMed ID: 11862476
    [Abstract] [Full Text] [Related]

  • 16. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F.
    J Immunol; 1998 Jun 01; 160(11):5669-75. PubMed ID: 9605174
    [Abstract] [Full Text] [Related]

  • 17. Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer.
    Reome JB, Hylind JC, Dutton RW, Dobrzanski MJ.
    Clin Immunol; 2004 Apr 01; 111(1):69-81. PubMed ID: 15093554
    [Abstract] [Full Text] [Related]

  • 18. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
    Rayman P, Uzzo RG, Kolenko V, Bloom T, Cathcart MK, Molto L, Novick AC, Bukowski RM, Hamilton T, Finke JH.
    Cancer J Sci Am; 2000 Feb 01; 6 Suppl 1():S81-7. PubMed ID: 10685665
    [Abstract] [Full Text] [Related]

  • 19. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
    Elsässer-Beile U, Gierschner D, Welchner T, Wetterauer U.
    Anticancer Res; 2003 Feb 01; 23(1A):433-7. PubMed ID: 12680244
    [Abstract] [Full Text] [Related]

  • 20. Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma.
    Yoong KF, Afford SC, Jones R, Aujla P, Qin S, Price K, Hubscher SG, Adams DH.
    Hepatology; 1999 Jul 01; 30(1):100-11. PubMed ID: 10385645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.